Ado-trastuzumab emtansine – The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancer
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer comprises around 20%–25% of breast cancers. With the discovery of trastuzumab, there was a marked improvement in the survival of patients with HER2-positive breast cancer both in curative and metastatic settings. However, patient...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2020-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=2;spage=218;epage=220;aulast= |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850045827963158528 |
|---|---|
| author | Sandip Ganguly Joydeep Ghosh Bivas Biswas Deepak Dabkara |
| author_facet | Sandip Ganguly Joydeep Ghosh Bivas Biswas Deepak Dabkara |
| author_sort | Sandip Ganguly |
| collection | DOAJ |
| description | Human epidermal growth factor receptor 2 (HER2)-positive breast cancer comprises around 20%–25% of breast cancers. With the discovery of trastuzumab, there was a marked improvement in the survival of patients with HER2-positive breast cancer both in curative and metastatic settings. However, patients with trastuzumab will eventually progress or develop recurrences. Newer anti-HER2 therapies have evolved to improve the outcome of this group of patients. One of them is monoclonal antibody–drug conjugate which is ado-trastuzumab emtansine. |
| format | Article |
| id | doaj-art-403e7c831fbb4ed08e1284f7d10d09f6 |
| institution | DOAJ |
| issn | 0971-5851 0975-2129 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Medical and Paediatric Oncology |
| spelling | doaj-art-403e7c831fbb4ed08e1284f7d10d09f62025-08-20T02:54:36ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58510975-21292020-01-0141221822010.4103/ijmpo.ijmpo_246_19Ado-trastuzumab emtansine – The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancerSandip GangulyJoydeep GhoshBivas BiswasDeepak DabkaraHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer comprises around 20%–25% of breast cancers. With the discovery of trastuzumab, there was a marked improvement in the survival of patients with HER2-positive breast cancer both in curative and metastatic settings. However, patients with trastuzumab will eventually progress or develop recurrences. Newer anti-HER2 therapies have evolved to improve the outcome of this group of patients. One of them is monoclonal antibody–drug conjugate which is ado-trastuzumab emtansine.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=2;spage=218;epage=220;aulast=breast cancerhuman epidermal growth factor receptor 2 positivetrastuzumab emtansine |
| spellingShingle | Sandip Ganguly Joydeep Ghosh Bivas Biswas Deepak Dabkara Ado-trastuzumab emtansine – The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancer Indian Journal of Medical and Paediatric Oncology breast cancer human epidermal growth factor receptor 2 positive trastuzumab emtansine |
| title | Ado-trastuzumab emtansine – The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancer |
| title_full | Ado-trastuzumab emtansine – The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancer |
| title_fullStr | Ado-trastuzumab emtansine – The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancer |
| title_full_unstemmed | Ado-trastuzumab emtansine – The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancer |
| title_short | Ado-trastuzumab emtansine – The monoclonal drug conjugate in human epidermal growth factor receptor 2-positive breast cancer |
| title_sort | ado trastuzumab emtansine the monoclonal drug conjugate in human epidermal growth factor receptor 2 positive breast cancer |
| topic | breast cancer human epidermal growth factor receptor 2 positive trastuzumab emtansine |
| url | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=2;spage=218;epage=220;aulast= |
| work_keys_str_mv | AT sandipganguly adotrastuzumabemtansinethemonoclonaldrugconjugateinhumanepidermalgrowthfactorreceptor2positivebreastcancer AT joydeepghosh adotrastuzumabemtansinethemonoclonaldrugconjugateinhumanepidermalgrowthfactorreceptor2positivebreastcancer AT bivasbiswas adotrastuzumabemtansinethemonoclonaldrugconjugateinhumanepidermalgrowthfactorreceptor2positivebreastcancer AT deepakdabkara adotrastuzumabemtansinethemonoclonaldrugconjugateinhumanepidermalgrowthfactorreceptor2positivebreastcancer |